KYTX
Kyverna Therapeutics, Inc.
Biotechnology
Market Cap$407M
5Y Perf.-65.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KYTX vs AUTL
Revenue, margins, valuation, and 5-year total return — side by side.
AUTL
Autolus Therapeutics plc
Biotechnology
Market Cap$410M
5Y Perf.-73.3%
KYTX vs AUTL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KYTX | AUTL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $407M | $410M |
| Revenue (TTM) | $0.00 | $51M |
| Net Income (TTM) | $-161M | $-225M |
| Gross Margin | — | -309.4% |
| Operating Margin | — | -8.6% |
| Total Debt | $8M | $53M |
| Cash & Equiv. | $97M | $227M |
KYTX vs AUTL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KYTX
AUTL
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Kyverna Therapeutic… (KYTX) | 100 | 34.2 | -65.8% |
| Autolus Therapeutic… (AUTL) | 100 | 26.8 | -73.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KYTX vs AUTL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AUTL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Kyverna Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KYTX
Kyverna Therapeutics, Inc.
The Long-Run Compounder
KYTX is the clearest fit if your priority is long-term compounding.
- -69.0% 10Y total return vs AUTL's -93.6%
- 5.0% margin vs AUTL's -439.7%
- +360.4% vs AUTL's +30.5%
Best for: long-term compounding
AUTL
Autolus Therapeutics plc
The Income Pick
AUTL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.95
- Rev growth 496.0%, EPS growth 27.5%, 3Y rev CAGR 88.7%
- Lower volatility, beta 1.95, Low D/E 12.3%, current ratio 10.88x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AUTL | 496.0% revenue growth vs KYTX's -91.8% |
| Quality / Margins | KYTX | 5.0% margin vs AUTL's -439.7% |
| Stability / Safety | AUTL | Beta 1.95 vs KYTX's 3.05 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYTX | +360.4% vs AUTL's +30.5% |
| Efficiency (ROA) | AUTL | -34.0% ROA vs KYTX's -86.0%, ROIC -204.1% vs -106.0% |
KYTX vs AUTL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
KYTX vs AUTL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAUTLLAGGINGKYTX
KYTXKyverna Therapeutics,…
1leads
AUTLAutolus Therapeutics …
2leads
6 Total Categories
CATEGORYLEADERvs KYTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AUTL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AUTL5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KYTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AUTL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AUTL and KYTX operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $51M |
| EBITDAEarnings before interest/tax | -$170M | -$427M |
| Net IncomeAfter-tax profit | -$161M | -$225M |
| Free Cash FlowCash after capex | -$158M | -$278M |
| Gross MarginGross profit ÷ Revenue | — | -3.1% |
| Operating MarginEBIT ÷ Revenue | — | -8.6% |
| Net MarginNet income ÷ Revenue | — | -4.4% |
| FCF MarginFCF ÷ Revenue | — | -5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -6.3% | +3.2% |
AUTL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KYTX and AUTL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| Market CapShares × price | $407M | $410M |
| Enterprise ValueMkt cap + debt − cash | $319M | $235M |
| Trailing P/EPrice ÷ TTM EPS | -2.79x | -1.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 40.47x |
| Price / BookPrice ÷ Book value/share | 1.34x | 0.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KYTX and AUTL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
AUTL leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
AUTL delivers a -84.7% return on equity — every $100 of shareholder capital generates $-85 in annual profit, vs $-106 for KYTX. KYTX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to AUTL's 0.12x.
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -106.0% | -84.7% |
| ROA (TTM)Return on assets | -86.0% | -34.0% |
| ROICReturn on invested capital | -106.0% | -2.0% |
| ROCEReturn on capital employed | -87.4% | -45.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 0.12x |
| Net DebtTotal debt minus cash | -$88M | -$175M |
| Cash & Equiv.Liquid assets | $97M | $227M |
| Total DebtShort + long-term debt | $8M | $53M |
| Interest CoverageEBIT ÷ Interest expense | -2204.37x | -25.98x |
AUTL leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KYTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYTX five years ago would be worth $3,100 today (with dividends reinvested), compared to $2,989 for AUTL. Over the past 12 months, KYTX leads with a +360.4% total return vs AUTL's +30.5%. The 3-year compound annual growth rate (CAGR) favors AUTL at -5.1% vs KYTX's -32.3% — a key indicator of consistent wealth creation.
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | +6.0% | -14.2% |
| 1-Year ReturnPast 12 months | +360.4% | +30.5% |
| 3-Year ReturnCumulative with dividends | -69.0% | -14.6% |
| 5-Year ReturnCumulative with dividends | -69.0% | -70.1% |
| 10-Year ReturnCumulative with dividends | -69.0% | -93.6% |
| CAGR (3Y)Annualised 3-year return | -32.3% | -5.1% |
KYTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYTX and AUTL each lead in 1 of 2 comparable metrics.
Risk & Volatility
AUTL is the less volatile stock with a 1.95 beta — it tends to amplify market swings less than KYTX's 3.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYTX currently trades 68.0% from its 52-week high vs AUTL's 59.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.05x | 1.95x |
| 52-Week HighHighest price in past year | $13.67 | $2.70 |
| 52-Week LowLowest price in past year | $1.95 | $1.15 |
| % of 52W HighCurrent price vs 52-week peak | +68.0% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 64.3 |
| Avg Volume (50D)Average daily shares traded | 869K | 1.6M |
Evenly matched — KYTX and AUTL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KYTX as "Buy" and AUTL as "Buy". Consensus price targets imply 452.6% upside for AUTL (target: $9) vs 251.3% for KYTX (target: $33).
| Metric | KYTXKyverna Therapeut… | AUTLAutolus Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $32.67 | $8.87 |
| # AnalystsCovering analysts | 4 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AUTL leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KYTX leads in 1 (Total Returns). 2 tied.
Best OverallAutolus Therapeutics plc (AUTL)Leads 2 of 6 categories
Loading custom metrics...
KYTX vs AUTL: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is KYTX or AUTL a better buy right now?
Analysts rate Kyverna Therapeutics, Inc.
(KYTX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYTX or AUTL?
Over the past 5 years, Kyverna Therapeutics, Inc.
(KYTX) delivered a total return of -69. 0%, compared to -70. 1% for Autolus Therapeutics plc (AUTL). Over 10 years, the gap is even starker: KYTX returned -69. 0% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYTX or AUTL?
By beta (market sensitivity over 5 years), Autolus Therapeutics plc (AUTL) is the lower-risk stock at 1.
95β versus Kyverna Therapeutics, Inc. 's 3. 05β — meaning KYTX is approximately 56% more volatile than AUTL relative to the S&P 500. On balance sheet safety, Kyverna Therapeutics, Inc. (KYTX) carries a lower debt/equity ratio of 3% versus 12% for Autolus Therapeutics plc — giving it more financial flexibility in a downturn.
04Which has better profit margins — KYTX or AUTL?
Kyverna Therapeutics, Inc.
(KYTX) is the more profitable company, earning 0. 0% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYTX leads at 0. 0% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — KYTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — KYTX or AUTL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is KYTX or AUTL better for a retirement portfolio?
For long-horizon retirement investors, Autolus Therapeutics plc (AUTL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Kyverna Therapeutics, Inc. (KYTX) carries a higher beta of 3. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUTL: -93. 6%, KYTX: -69. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between KYTX and AUTL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KYTX is a small-cap quality compounder stock; AUTL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.